Die folgenden Links führen aus den jeweiligen lokalen Bibliotheken zum Volltext:
Alternativ können Sie versuchen, selbst über Ihren lokalen Bibliothekskatalog auf das gewünschte Dokument zuzugreifen.
Bei Zugriffsproblemen kontaktieren Sie uns gern.
9 Ergebnisse
Sortierung:
In: Studies in Third World societies 44
In: New directions for program evaluation: a quarterly sourcebook, Band 1989, Heft 42, S. 49-50
ISSN: 1534-875X
AbstractJohn P. Mason comments on Randal Joy Thompson's chapter, "Evaluator as Power Broker: Issues in the Maghreb."
In: The Middle East journal, Band 36, Heft 3, S. 319
ISSN: 0026-3141
In: The Middle East journal, Band 36, S. 319-335
ISSN: 0026-3141
In: The Middle East journal, Band 35, Heft 1, S. 61
ISSN: 0026-3141
In: Man: the journal of the Royal Anthropological Institute of Great Britain and Ireland, Band 13, Heft 3, S. 490
The development of severe mental health conditions is strongly linked to our environments, particularly experiences of trauma and adversity. However treatments for severe mental health conditions are often primarily biomedical, centred around medication. In the case of schizophrenia and psychosis, this is antipsychotic medication. Although antipsychotics have been found to reduce symptoms and risk of relapse, some patients derive little benefit from these drugs, and they can lead to severe adverse effects. Subsequently a high proportion of people do not want to take antipsychotics and request an alternative. Yet in the UK and in many countries there are currently no guidelines for stopping antipsychotics or formal treatment alternatives, despite such alternatives being available in some countries. For example, in Norway and Vermont (USA), in response to pressure from service user organisations, governments have mandated the establishment of 'minimal medication' services. We examine whether everyone with a psychotic condition needs long-term antipsychotic treatment and evidence for alternative models of care. We recommend that healthcare providers should be encouraged to develop a psychosocial treatment package for people with psychosis or schizophrenia that provides a realistic possibility of minimising antipsychotic exposure.
BASE